Vulvovaginal candidiasis-an overview of current trends and the latest treatment strategies.
Bhosale VB, Koparde AA, Thorat VM.
Microb Pathog. 2025 Mar;200:107359. doi: 10.1016/j.micpath.2025.107359. Epub 2025 Feb 5.
PMID:39921042
Oteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial.
Wang X, Chen L, Ruan H, Xiong Z, Wang W, Qiu J, Song W, Zhang C, Xue F, Qin T, Zhang B, An R, Luo X, Wang W, Zhang S, Cai Y, Kang J, Deng H, Fan S, Cui M, Wang S, Luo X, Su Z, Shu J, Wang Q, Wang F, Bai J, Liao Q.
Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0077823. doi: 10.1128/aac.00778-23. Epub 2023 Dec 14.
PMID:38095426
Recurrent vulvovaginal candidiasis.
Lines A, Vardi-Flynn I, Searle C.
BMJ. 2020 Jun 8;369:m1995. doi: 10.1136/bmj.m1995.
Rodríguez-Cerdeira C, Gregorio MC, Molares-Vila A, López-Barcenas A, Fabbrocini G, Bardhi B, Sinani A, Sánchez-Blanco E, Arenas-Guzmán R, Hernandez-Castro R.
Colloids Surf B Biointerfaces. 2019 Feb 1;174:110-125. doi: 10.1016/j.colsurfb.2018.11.011. Epub 2018 Nov 7.